Autolus Therapeutics announces publication in Nature Communications
22 févr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in Nature Communications
Autolus Therapeutics announces publication in ACS Chemical Biology
23 janv. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in ACS Chemical Biology
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
05 sept. 2023 07h00 HE
|
Autolus Therapeutics plc
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
06 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years...
Autolus Therapeutics announces publication in Cancer Immunology Research
27 juin 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
26 avr. 2023 16h01 HE
|
Autolus Therapeutics plc
LONDON, April 26, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication in Molecular Therapy
04 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
- Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR - AUTO1/22 may reduce CD19 negative escape in children with B-ALL, and may have broader applications in...
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
12 déc. 2022 10h00 HE
|
Autolus Therapeutics plc
Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia...
Moderna exercises option to license proprietary targeting technology from Autolus
12 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna - - Autolus receives option exercise fee, with potential for development milestone payments plus...
Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress
10 juin 2022 03h01 HE
|
Autolus Therapeutics plc
- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for...